Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 7/20 | 0.42 |
| ▸ | BACE1 | P56817 | 7/20 | 0.42 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873997 | 1.00 | CTSD (0.42) | CTSDBACE1SPPL2ABACE2PTGES | |
| SCHEMBL6618272 | 0.99 | CTSD (0.41) | CTSDBACE1SPPL2ABACE2PTGES | |
| SCHEMBL4869483 | 0.91 | ADAMTS4 (0.43) | CTSD | |
| SCHEMBL4869489 | 0.91 | ADAMTS4 (0.43) | CTSD | |
| SCHEMBL4862414 | 0.90 | CTSD (0.44) | CTSDBACE1SPPL2ABACE2 | |
| SCHEMBL4862405 | 0.90 | CTSD (0.44) | CTSDBACE1SPPL2ABACE2 | |
| SCHEMBL4874282 | 0.89 | KLK5 (0.43) | CTSDBACE1SPPL2A | |
| SCHEMBL4874277 | 0.89 | KLK5 (0.43) | CTSDBACE1SPPL2A | |
| SCHEMBL4877803 | 0.88 | CTSD (0.44) | CTSDBACE1SPPL2ABACE2 | |
| SCHEMBL4877795 | 0.88 | CTSD (0.44) | CTSDBACE1SPPL2ABACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSD 93/4885BACE1 69/4885SPPL2A 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.